Skip to content
Companies

NK-One Therapeutics

Spinal injection therapy for intractable cancer pain

Raised to date

$290K

of $310K offered across 1 Form D filing

Still open
$20K
Investors
7
Last filed
Apr 27, 2026

About

NK-One Therapeutics is a Wayne, Pennsylvania biotechnology company developing a precision therapy for refractory cancer pain. Its lead program, Substance P-Saporin (SP-SAP), licensed from Advanced Targeting Systems, is given as a single intrathecal administration to selectively disable NK-1 receptor-expressing pain neurons in the spinal dorsal horn while preserving protective acute pain signaling. The company holds worldwide development rights to SP-SAP for human and veterinary use; a Phase 1 human trial is underway and a large canine clinical trial has been completed.

A 'molecular scalpel' approach: a one-time intrathecal treatment that selectively targets NK-1R-expressing pain neurons, with efficacy already shown in a large canine clinical trial and rights covering both human and animal use.

Funding

  • Security to be acquiredFiled Apr 27, 2026Form D
    $290K/ $310K

Product

SP-SAP (Substance P-Saporin)

Drug candidate

A substance P-saporin conjugate delivered intrathecally that selectively disables neurokinin-1 receptor-expressing neurons in the spinal dorsal horn to halt intractable cancer pain.

  • Single intrathecal administration
  • Selective targeting of NK-1 receptor-expressing pain neurons
  • Preserves protective acute pain signaling pathways

Built for

End-stage cancer patients with intractable pain, and companion animals with cancer pain

People on file